INNOVIVA, INC. Operating Expenses
INNOVIVA, INC. (INVA) reported Operating Expenses of $39.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- INNOVIVA, INC. operating expenses for the quarter ending 2026-06-30 was $39.76M, a 15.60% increase year-over-year.
- INNOVIVA, INC. operating expenses for the quarter ending 2026-03-31 was $37.68M, a 18.16% increase year-over-year.
- INNOVIVA, INC. operating expenses for the quarter ending 2025-12-31 was $36.68M, a 4.82% increase year-over-year.
- INNOVIVA, INC. operating expenses for the quarter ending 2025-09-30 was $40.96M, a 37.59% increase year-over-year.
- INNOVIVA, INC. operating expenses for fiscal 2025 was $143.92M, a 11.27% increase from fiscal 2024.
- INNOVIVA, INC. operating expenses for fiscal 2024 was $129.34M, a 2.13% decline from fiscal 2023.
- INNOVIVA, INC. operating expenses for fiscal 2023 was $132.15M.
- INNOVIVA, INC. operating expenses for fiscal 2021 was $16.76M, a 6.97% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.76M 10-Q · filed 2026-08-05 | $77.44M 10-Q · filed 2026-08-05 | $114.12M derived: sum of 3 quarters · filed 2026-08-05 | $155.08M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $37.68M 10-Q · filed 2026-05-06 | $74.36M derived: sum of 2 quarters · filed 2026-05-06 | $115.32M derived: sum of 3 quarters · filed 2026-05-06 | $149.71M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $36.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $77.64M derived: sum of 2 quarters · filed 2026-02-25 | $112.03M derived: sum of 3 quarters · filed 2026-08-05 | $143.92M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $40.96M 10-Q · filed 2025-11-05 | $75.36M derived: sum of 2 quarters · filed 2026-08-05 | $107.24M 10-Q · filed 2025-11-05 | $142.23M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $34.40M 10-Q · filed 2026-08-05 | $66.28M 10-Q · filed 2026-08-05 | $101.27M derived: sum of 3 quarters · filed 2026-08-05 | $131.04M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $31.89M 10-Q · filed 2026-05-06 | $66.88M derived: sum of 2 quarters · filed 2026-05-06 | $96.65M derived: sum of 3 quarters · filed 2026-05-06 | $126.95M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $34.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $64.76M derived: sum of 2 quarters · filed 2026-02-25 | $95.06M derived: sum of 3 quarters · filed 2026-02-25 | $129.34M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $29.77M 10-Q · filed 2025-11-05 | $60.07M derived: sum of 2 quarters · filed 2025-11-05 | $94.35M 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | $30.30M 10-Q · filed 2025-08-06 | $64.58M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | $34.28M 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | $132.15M 10-K · filed 2026-02-25 | |||||||
| 2022-09-30 | -$219.17M 10-Q · filed 2022-11-09 | -$193.50M derived: sum of 2 quarters · filed 2022-11-09 | -$86.10M 10-Q · filed 2022-11-09 | -$59.81M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2022-06-30 | $25.67M 10-Q · filed 2022-07-27 | $38.00M 10-Q · filed 2022-07-27 | $159.36M derived: sum of 3 quarters · filed 2022-07-27 | $134.04M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2022-03-31 | $12.33M 10-Q · filed 2022-05-05 | $133.69M derived: sum of 2 quarters · filed 2022-05-05 | $108.38M derived: sum of 3 quarters · filed 2022-11-09 | $112.64M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-12-31 | $121.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $96.05M derived: sum of 2 quarters · filed 2022-11-09 | $100.31M derived: sum of 3 quarters · filed 2022-11-09 | $16.76M 10-K/A · filed 2022-03-17 | ||||
| 2021-09-30 | -$25.32M 10-Q · filed 2022-11-09 | $3.31M 10-Q · filed 2021-10-27 | -$21.05M derived: sum of 2 quarters · filed 2022-11-09 | -$104.60M 10-Q · filed 2022-11-09 | $13.61M 10-Q · filed 2021-10-27 | -$9.32M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $4.27M 10-Q · filed 2022-07-27 | $10.30M 10-Q · filed 2022-07-27 | $15.99M derived: sum of 3 quarters · filed 2022-07-27 | $20.25M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | $6.04M 10-Q · filed 2022-05-05 | $11.72M derived: sum of 2 quarters · filed 2022-05-05 | $15.99M derived: sum of 3 quarters · filed 2022-05-05 | $19.14M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $5.69M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $9.95M derived: sum of 2 quarters · filed 2022-03-17 | $13.11M derived: sum of 3 quarters · filed 2022-03-17 | $15.67M 10-K/A · filed 2022-03-17 | ||||
| 2020-09-30 | $4.26M 10-Q · filed 2021-10-27 | $7.42M derived: sum of 2 quarters · filed 2021-10-27 | $9.98M 10-Q · filed 2021-10-27 | $12.31M derived: sum of 4 quarters · filed 2021-10-27 | ||||
| 2020-06-30 | $3.15M 10-Q · filed 2021-07-29 | $5.72M 10-Q · filed 2021-07-29 | $8.05M derived: sum of 3 quarters · filed 2021-07-29 | $13.01M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | $2.56M 10-Q · filed 2021-04-28 | $4.89M derived: sum of 2 quarters · filed 2021-04-28 | $9.86M derived: sum of 3 quarters · filed 2021-04-28 | $14.20M derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | $2.33M 10-K · filed 2020-02-19 | $7.29M derived: sum of 2 quarters · filed 2020-10-28 | $11.64M derived: sum of 3 quarters · filed 2020-10-28 | $14.66M 10-K/A · filed 2022-03-17 | ||||
| 2019-09-30 | $4.96M 10-Q · filed 2020-10-28 | $9.31M derived: sum of 2 quarters · filed 2020-10-28 | $12.32M 10-Q · filed 2020-10-28 | $14.96M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $4.35M 10-Q · filed 2020-07-29 | $7.36M 10-Q · filed 2020-07-29 | $10.00M derived: sum of 3 quarters · filed 2020-07-29 | $14.02M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $3.02M 10-Q · filed 2020-04-29 | $5.65M derived: sum of 2 quarters · filed 2020-04-29 | $9.67M derived: sum of 3 quarters · filed 2020-04-29 | $14.08M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-31 | $2.64M 10-K · filed 2020-02-19 | -$2.64M 10-K · filed 2019-02-19 | $6.66M derived: sum of 2 quarters · filed 2020-02-19 | $11.07M derived: sum of 3 quarters · filed 2020-02-19 | $22.75M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $4.02M 10-K · filed 2020-02-19 | $8.43M derived: sum of 2 quarters · filed 2020-02-19 | $20.11M 10-Q · filed 2019-10-30 | $23.23M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-06-30 | $4.41M 10-K · filed 2020-02-19 | $16.10M 10-Q · filed 2019-07-24 | $19.21M derived: sum of 3 quarters · filed 2020-02-19 | $27.83M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-03-31 | $11.69M 10-K · filed 2020-02-19 | $14.80M derived: sum of 2 quarters · filed 2020-02-19 | $23.42M derived: sum of 3 quarters · filed 2020-02-19 | $34.15M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2017-12-31 | $3.11M 10-K · filed 2019-02-19 | $11.73M derived: sum of 2 quarters · filed 2019-02-19 | $22.46M derived: sum of 3 quarters · filed 2019-02-19 | $33.61M 10-K · filed 2020-02-19 | ||||
| 2017-09-30 | $8.62M 10-K · filed 2019-02-19 | $19.35M derived: sum of 2 quarters · filed 2019-02-19 | $30.50M 10-Q · filed 2018-10-31 | $36.45M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-06-30 | $10.73M 10-K · filed 2019-02-19 | $21.88M 10-Q · filed 2018-07-26 | $27.83M derived: sum of 3 quarters · filed 2019-02-19 | $33.22M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-03-31 | $11.15M 10-K · filed 2019-02-19 | $17.10M derived: sum of 2 quarters · filed 2019-02-19 | $22.49M derived: sum of 3 quarters · filed 2019-02-19 | $29.09M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2016-12-31 | $5.95M 10-K · filed 2018-02-23 | $5.60M 10-K · filed 2017-02-28 | $11.34M derived: sum of 2 quarters · filed 2018-02-23 | $17.94M derived: sum of 3 quarters · filed 2018-02-23 | $24.58M 10-K · filed 2019-02-19 | |||
| 2016-09-30 | $5.39M 10-K · filed 2018-02-23 | $11.99M derived: sum of 2 quarters · filed 2018-02-23 | $18.63M 10-Q · filed 2017-11-03 | $24.17M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $6.59M 10-K · filed 2018-02-23 | $13.24M 10-Q · filed 2017-08-08 | $18.78M derived: sum of 3 quarters · filed 2018-02-23 | $23.91M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $6.64M 10-K · filed 2018-02-23 | $12.19M derived: sum of 2 quarters · filed 2018-02-23 | $17.32M derived: sum of 3 quarters · filed 2018-02-23 | $22.86M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $5.54M 10-K · filed 2017-02-28 | $10.67M derived: sum of 2 quarters · filed 2017-02-28 | $16.22M derived: sum of 3 quarters · filed 2017-02-28 | $22.37M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $5.13M 10-K · filed 2017-02-28 | $10.68M derived: sum of 2 quarters · filed 2017-02-28 | $16.83M 10-Q · filed 2016-11-03 | $23.98M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $5.55M 10-K · filed 2017-02-28 | $11.70M 10-Q · filed 2016-08-04 | $18.85M derived: sum of 3 quarters · filed 2017-02-28 | $29.39M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $6.15M 10-K · filed 2017-02-28 | $13.30M derived: sum of 2 quarters · filed 2017-02-28 | $23.84M derived: sum of 3 quarters · filed 2017-02-28 | $34.57M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $7.15M 10-K · filed 2016-02-24 | $17.69M derived: sum of 2 quarters · filed 2016-02-24 | $28.42M derived: sum of 3 quarters · filed 2016-02-24 | $42.36M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $10.54M 10-K · filed 2016-02-24 | $21.27M derived: sum of 2 quarters · filed 2016-02-24 | $35.21M 10-Q · filed 2015-11-05 | $44.10M derived: sum of 4 quarters · filed 2016-02-24 | ||||
| 2014-06-30 | $10.73M 10-K · filed 2016-02-24 | $24.67M 10-Q · filed 2015-08-06 | $33.56M derived: sum of 3 quarters · filed 2016-02-24 | $41.68M derived: sum of 4 quarters · filed 2016-02-24 | ||||
| 2014-03-31 | $13.94M 10-K · filed 2016-02-24 | $66.41M 10-Q · filed 2014-05-07 | $22.83M derived: sum of 2 quarters · filed 2016-02-24 | $30.95M derived: sum of 3 quarters · filed 2016-02-24 | $39.17M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $8.89M 10-K · filed 2015-02-27 | $17.01M derived: sum of 2 quarters · filed 2015-02-27 | $25.23M derived: sum of 3 quarters · filed 2015-02-27 | $33.33M 10-K · filed 2016-02-24 | $173.62M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | $8.12M 10-K · filed 2015-02-27 | $45.68M 10-Q · filed 2013-11-01 | $16.34M derived: sum of 2 quarters · filed 2015-02-27 | $24.44M 10-Q · filed 2014-11-04 | $123.52M 10-Q · filed 2013-11-01 | -$57.78M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $8.22M 10-K · filed 2015-02-27 | $43.11M 10-Q · filed 2013-08-01 | $16.32M 10-Q · filed 2014-08-07 | $77.84M 10-Q · filed 2013-08-01 | -$65.91M derived: sum of 3 quarters · filed 2015-02-27 | -$31.13M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $8.10M 10-K · filed 2015-02-27 | $34.73M 10-Q · filed 2013-05-01 | -$74.13M derived: sum of 2 quarters · filed 2015-02-27 | -$39.34M derived: sum of 3 quarters · filed 2015-02-27 | -$2.21M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | -$82.22M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$47.44M derived: sum of 2 quarters · filed 2015-02-27 | -$10.30M derived: sum of 3 quarters · filed 2015-02-27 | $30.76M 10-K · filed 2015-02-27 | $148.76M 10-K · filed 2013-02-26 | |||
| 2012-09-30 | $34.78M 10-Q · filed 2013-11-01 | $71.92M derived: sum of 2 quarters · filed 2013-11-01 | $112.98M 10-Q · filed 2013-11-01 | $153.91M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | $37.14M 10-Q · filed 2013-08-01 | $78.20M 10-Q · filed 2013-08-01 | $119.14M derived: sum of 3 quarters · filed 2014-03-03 | $154.77M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | $41.06M 10-Q · filed 2013-05-01 | $82.00M derived: sum of 2 quarters · filed 2014-03-03 | $117.63M derived: sum of 3 quarters · filed 2014-03-03 | $147.68M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2011-12-31 | $40.94M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $76.57M derived: sum of 2 quarters · filed 2014-03-03 | $106.62M derived: sum of 3 quarters · filed 2014-03-03 | $134.25M 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | $35.63M 10-Q · filed 2012-10-31 | $65.68M derived: sum of 2 quarters · filed 2012-10-31 | $93.31M 10-Q · filed 2012-10-31 | $118.19M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $30.05M 10-Q · filed 2012-08-01 | $57.68M 10-Q · filed 2012-08-01 | $82.55M derived: sum of 3 quarters · filed 2013-02-26 | $107.70M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $27.63M 10-Q · filed 2012-05-02 | $52.51M derived: sum of 2 quarters · filed 2013-02-26 | $77.66M derived: sum of 3 quarters · filed 2013-02-26 | $103.35M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $24.88M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $50.02M derived: sum of 2 quarters · filed 2013-02-26 | $75.72M derived: sum of 3 quarters · filed 2013-02-26 | $102.55M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $25.15M 10-Q · filed 2011-11-02 | $50.84M derived: sum of 2 quarters · filed 2011-11-02 | $77.67M 10-Q · filed 2011-11-02 | |||||
| 2010-06-30 | $25.70M 10-Q · filed 2011-08-03 | $52.52M 10-Q · filed 2011-08-03 | ||||||
| 2009-12-31 | $105.73M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |